IL6 and breast cancer: To reduce the probability of saturating the cell’s capacity to produce IL-6 and to better assess a possible synergistic interaction between OSM and IL-1β in breast cancer cells, we decreased the amount of OSM used in the experiments from 25 ng/mL to 10 ng/mL.